Contravisory Investment Management’s Edwards Lifesciences EW Stock Holding History

Contravisory Investment Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-51	Closed	-$7K	–	350
2021 Q4	$7K	Hold	51	–	–	﹤0.01%	263
2021 Q3	$6K	Hold	51	–	–	﹤0.01%	257
2021 Q2	$5K	Hold	51	–	–	﹤0.01%	254
2021 Q1	$4K	Hold	51	–	–	﹤0.01%	255
2020 Q4	$5K	Hold	51	–	–	﹤0.01%	236
2020 Q3	$4K	Hold	51	–	–	﹤0.01%	234
2020 Q2	$4K	Hold	51	–	–	﹤0.01%	234
2020 Q1	$3K	Buy	+51	New	+$3.68K	﹤0.01%	259
2017 Q1	–	Sell	-630	Closed	-$20K	–	302
2016 Q4	$20K	Buy	630 +255	+68%	+$8.26K	0.01%	184
2016 Q3	$15K	Buy	+375	New	+$14.1K	﹤0.01%	149
2015 Q4	–	Sell	-360	Closed	-$9K	–	219
2015 Q3	$9K	Hold	360	–	–	﹤0.01%	130
2015 Q2	$9K	Hold	360	–	–	﹤0.01%	149
2015 Q1	$9K	Hold	360	–	–	﹤0.01%	125
2014 Q4	$8K	Hold	360	–	–	﹤0.01%	129
2014 Q3	$6K	Buy	+360	New	+$5.68K	﹤0.01%	134

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Contravisory Investment Management's EW Position: Q1 2022 in Review

Contravisory Investment Management sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 51 shares — an estimated $7K sold.

Contravisory Investment Management first reported a position in EW in Q3 2014 and held it in 15 quarters. The position peaked at $20K in Q4 2016. 1,312 funds tracked by Wall St. Rank hold EW as of Q1 2022.

Contravisory Investment Management reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
Contravisory Investment Management sold 51 Edwards Lifesciences shares in Q1 2022, an estimated $7K.
Contravisory Investment Management first reported a position in Edwards Lifesciences in Q3 2014 and held it in 15 quarters.
Contravisory Investment Management's Edwards Lifesciences position peaked at $20K in Q4 2016.
1,312 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Contravisory Investment Management's 13F filing for Q1 2022, filed 8 Apr 2022.